Roivant Sciences Ltd. (“Roivant” or the “Company”) is building the next-generation ‘‘big pharma’’ company, organized to harness modern technologies and computational tools as well as the entrepreneurial spirit of nimble biotechnology companies at scale. Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. The Company is a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. Roivant combines the team’s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. The Company deploys a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. Roivant then seeks to acquire, in-license or discover promising drug candidates against those targets or pathways. The Company’s small molecule discovery engine is powered by leading computational physics and machine learning (‘‘ML’’) capabilities for in silico drug design.